Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
Latest news on NOVO NORDISK A/S
12/09 NOVO NORDISK A/S : Smithfield chamber, residents oppose jail
12/08 NOVO NORDISK A/S : Patient Entrepreneur Brianna Wolin of Find Your Ditto Selecte..
12/06DJNovo Nordisk Pledges to Limit Price Increases in U.S. for Its Drugs
12/06 NOVO NORDISK A/S : NovoSeven resolved 96.5% of bleeds in haemophilia A or B suff..
12/05 NOVO NORDISK A/S : NovoSeven resolved 96.5% of bleeds when initiated within one ..
12/05 NOVO NORDISK A/S : Xultophy demonstrates similar glucose control with reduced ri..
12/05 NOVO NORDISK A/S : files for regulatory approval of once-weekly semaglutide in t..
12/05 NOVO NORDISK A/S : - Share repurchase programme
12/05 NOVO NORDISK A/S : NovoSeven® resolved 96.5% of bleeds when initiated within one..
12/02 NOVO NORDISK A/S : Xultophy® demonstrates similar glucose control with reduced r..
12/02 NOVO NORDISK A/S : Xultophy Demonstrates Similar Glucose Control with Reduced Ri..
12/01 NOVO NORDISK A/S : Patent Issued for Method and System for Self-Management of a ..
12/01 NOVO NORDISK A/S : Findings from Novo Nordisk Broaden Understanding of Pharmacol..
12/01 NOVO NORDISK A/S : Study Results from Novo Nordisk in the Area of Quality of Lif..
12/01 NOVO NORDISK A/S : Receives FDA Approval for Xultophy® 100/3.6 insulin degludec ..
11/29 NOVO NORDISK A/S : reports Tresiba insulin achieves target in study
11/29 NOVO NORDISK A/S : Tresiba® demonstrates a safe cardiovascular profile and reduc..
11/28 NOVO NORDISK A/S : - Share repurchase programme
11/27DJDrugmakers Find Competition Doesn't Keep a Lid on Prices
11/23 NOVO NORDISK A/S : Clayton, county launch sewer authority
11/23 US FDA APPROVES SANOFI SA (NYSE : SNY) Soliqua 100/33, Novo Nordisk A/S (NYSE:NV..
11/22 NOVO NORDISK A/S : Findings from Novo Nordisk Provides New Data about Saccharomy..
11/22 REPORTS ON OBESITY FROM NOVO NORDISK : A Population Pharmacokinetic Analysis)
11/22 NOVO NORDISK A/S : receives US FDA approval for Xultophy 100/3.6
11/22 NOVO NORDISK A/S : receives US FDA approval for Xultophy 100/3.6
11/21 NOVO NORDISK A/S : receives US FDA approval for Xultophy® 100/3.6
11/21 NOVO NORDISK A/S : - Share repurchase programme
11/19 NOVO NORDISK A/S : Modern diabetes centre opened in Nakuru
11/19 Indian pharma companies missing on access to medicine index
11/18 Synlab ready to snap up more lab chains after debt deal
11/17 ORAMED : Chinese partner building plant for our product
11/17 NOVO NORDISK A/S : Patent Issued for Automatic Injection Device with Reset Featu..
11/17 NOVO NORDISK A/S : Patent Issued for Regulation of Food Preference Using GLP-1 A..
11/17 NOVO NORDISK A/S : Punjab govt, Denmark to collaborate for control of diabetes
11/17 NOVO NORDISK A/S : launches new basal insulin in Oman
11/17 NOVO NORDISK A/S : Punjab , Denmark govt to collaborate for control of diabetes ..
11/17 NOVO NORDISK A/S : Punjab Diabetes Forum to be held on Dec 6
11/17 NOVO NORDISK A/S : Team Novo Nordisk Announces 2017 Roster
11/17 SILENT KILLER : Health experts warn on rising cases of diabetes
11/16 NOVO NORDISK A/S : Punjab govt, Danish company to collaborate for diabetes preve..
11/15 Global Anti Obesity Drugs Market 2016- Pfizer, Merck, Roche, GlaxoSmithKline,..
11/15 NOVO NORDISK A/S : World Diabetes Day being observed today
11/14 NOVO NORDISK A/S : receives positive opinion from the European regulatory author..
11/14 NOVO NORDISK A/S : Danish envoy appreciates govt initiatives to improve health o..
11/14 NOVO NORDISK A/S : - Share repurchase programme
11/14 NOVO NORDISK A/S : Tresiba® demonstrated lower day-to-day and within-day variabi..
11/14 NOVO NORDISK A/S : expands programme to reach 20,000 children with diabetes in d..
11/11 NOVO NORDISK A/S : submits application in the EU for including data from the two..
11/11 NOVO NORDISK A/S : submits application in the EU for including data from the two..
11/11 NOVO NORDISK A/S : Trading in Novo Nordisk shares by board members, executives a..
11/11 NOVO NORDISK A/S : receives positive opinion from the European regulatory author..
11/10 NOVO NORDISK A/S : New study showed that only 55% of people with obesity have re..
11/10 NOVO NORDISK A/S : Findings from Novo Nordisk in the Area of Biopharmaceuticals ..
11/10 NOVO NORDISK A/S : submits application in the EU for including data from the two..
11/09 Pharma, biotech shares soar as Trump win calms pricing talk
11/09 Pharma, biotech shares soar as Trump win calms pricing talk
11/09 NOVO NORDISK A/S : Site Tianjin cuts emissions
11/08 Bernie Sanders calls on Justice Department to investigate Lilly over insulin ..
11/07 ROYAL BANK OF CANADA : Brookmont Capital Management Reached $1,683,000 Position ..
11/07 NOVO NORDISK A/S : - Share repurchase programme
11/04 NOVO NORDISK A/S : - New study showed that only 55% of people with obesity have ..
11/04 Drugmakers under fire for possible U.S. price fixing
11/03 FINDINGS FROM NOVO NORDISK YIELDS NE : ...
11/03 NOVO NORDISK A/S : New study showed that only 55% of people with obesity have re..
11/03 Sanders wants the feds to probe these drug companies for possible price collu..
11/02 NOVO NORDISK A/S : New data show post-meal hyperglycaemia is associated with a n..
11/02 NOVO NORDISK A/S : Trading in Novo Nordisk shares by board members, executives a..
11/02 NOVO NORDISK A/S : Team Novo Nordisk debuts China tour
11/01 NOVO NORDISK A/S (NYSE : NVO) Revisits New Strategy to Deal With U.S Payers
11/01 NOVO NORDISK A/S : Trading in Novo Nordisk shares by board members, executives a..
10/31 NOVO NORDISK A/S : increased adjusted operating profit by 7% in local currencies..
10/29 NOVO NORDISK A/S : increased adjusted operating profit by 7% in local currencies..
10/28DJU.S. HOT STOCKS : Hot Stocks to Watch
10/28DJSANOFI : Novo Nordisk Fortunes Diverge Amid Insulin Price Slump
10/28DJSANOFI : Novo Nordisk Fortunes Diverge Amid Insulin Price Slump
1  2  3  4  5  6  7  8  9  10Next
Advertisement
Financials ( DKK)
Sales 2016 111 925 M
EBIT 2016 48 801 M
Net income 2016 38 060 M
Finance 2016 12 285 M
Yield 2016 2,92%
P/E ratio 2016 16,23
P/E ratio 2017 15,31
EV / Sales 2016 4,27x
EV / Sales 2017 4,11x
Capitalization 490 663 M
More Financials
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | 4-Traders
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 32
Average target price 278  DKK
Spread / Average Target 14%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Lars Rebien Sørensen President & Chief Executive Officer
Göran Albert Ando Chairman
Jesper Brandgaard Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Mads Krogsgaard Chief Science Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S-39.23%70 014
JOHNSON & JOHNSON8.05%301 952
ROCHE HOLDING LTD.-19.97%189 184
PFIZER INC.-3.38%187 755
NOVARTIS AG-20.79%178 671
MERCK & CO., INC.13.82%165 759
More Results